Collegium Pharmaceutical, Inc. · NASDAQ:COLL
Collegium Pharmaceutical — Q3 2026 Earnings Presentation
22 slides from Collegium Pharmaceutical's earnings presentation, Nov 5, 2026
Slide 1: Q3 2026 Earnings Presentation
Actor portrayals Novemb er 5, 2026 | NA SDAQ: CO LL A commercial-stage biopharmaceutical company focused on improving the lives of people living with serious neurological and pain conditions Q3 2026 Earnings Presentation
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as "predicts," "forecasts," "believes," "potential," "proposed," "continue," "estimates," "anticipates,"
Slide 3: Business Overview and Commercial Update
Business Overview and Commercial Update Vikram Karnani President & Chief Executive Officer
Slide 4: Building a Leading, Diversified Biopharmaceutical Company
Building a Leading, Diversified Biopharmaceutical Company 1. This financial data represents the midpoint of 2026 financial guidance ranges provided by Collegium in its press release on Form 8-K filed with the SEC on November 5, 2026. 2. Represents a non-GAAP financial measure. Refer to “Non-GAAP Fin
Slide 5: Recent Business Highlights
Recent Business Highlights1 1. Unless otherwise noted, this financial data was provided by Collegium in its press release on Form 8-K and Quarterly Report on Form 10-Q filed with the SEC on November 5, 2026. 2. Represents a non-GAAP financial measure. Refer to “Non-GAAP Financial Measures” on slide
Slide 6: Strategic Priorities to Drive Value Creation
Drive further growth for ADHD Portfolio Strategic Priorities to Drive Value Creation Grows revenue Extends longevity Increases profitability Generates robust cash flows Diversifies portfolio Strengthens balance sheet VALUE CREATION 2026 Strategic Priorities Maximize the durability of the
Slide 7: ADHD Leadership and Strong Brand Fundamentals
ADHD Leadership and Strong Brand Fundamentals 1. ATU (Awareness, Trial, & Usage) Market Research Study, completed Q1 2026. 2. IQVIA NPA through September 2026. #1 highest rated1 branded ADHD medicine in terms of product differentiation ~30% share of branded, long-acting methylphenidate market2 #1 hi
Slide 8: Fastest Growing Stimulant for Treatment of ADHD
Fastest Growing Stimulant for Treatment of ADHD Q3'25 Q3'26 GROWTH IN QUARTERLY PRESCRIPTIONS1 +16% 192K 223K Q3'25 Q3'26 STRONG AND GROWING PRESCRIBER BASE2 +19% 28K 33K MARKET SHARE IN BRANDED LONG-ACTING METHYLPHENIDATE MARKET1 Q3'25 Q3'26 23% 30% +6.5 Percentage Points 1. IQVIA NPA through Septe
Slide 9: AZSTARYS is Well Positioned for Future Growth
1 AZSTARYS is Well Positioned for Future Growth GROWTH IN QUARTERLY PRESCRIPTIONS1 Note: AZSTARYS prescriptions declined by ~2% in 2025 prior to Collegium ownership1 2026 REVENUE OUTLOOK $65-75M in revenue expected between May 12 and December 31, 2026 IP Protection through 2037 1. IQVIA NPA through
Slide 10: 2026 Priorities: Driving Further Growth for ADHD Portfolio
2026 Priorities: Driving Further Growth for ADHD Portfolio • Increase awareness and adoption with expanded set of prescribers • Raise caregiver and patient awareness to drive HCP request • Increase depth of prescribing with targeted physicians • Successfully integrate AZSTARYS into portfolio • Accel
Slide 11: Maximizing the Value and Durability of the Pain Portfolio
Maximizing the Value and Durability of the Pain Portfolio 1. This financial data was provided by Collegium in its press release on Form 8-K and Quarterly Report on Form 10-Q filed with the SEC on November 5, 2026. 2. ATU (Awareness, Trial, & Usage) Market Research Study, fielded Q4 2022. #1 highest
Slide 12: Financial Highlights
Financial Highlights Colleen Tupper Executive Vice President & Chief Financial Officer
Slide 13: Q3'26 Financial Highlights
Q3’26 Financial Highlights1 1. This financial data was provided by Collegium in its press release on Form 8-K and Quarterly Report on Form 10-Q filed with the SEC on November 5, 2026. 2. Represents a non-GAAP financial measure. Refer to “Non-GAAP Financial Measures” on slide 2. Product Revenues, Net
Slide 14: 2026 Financial Guidance
2025 Actuals 2026 Guidance Range2 YoY Change3 Product Revenues, Net $781M $825 – 855M +8% JORNAY PM Revenue, Net $149M $190 - 200M +31% AZSTARYS Revenue, Net N/A4 $65 – 75M N/A Adjusted EBITDA1 $460M $445 – 470M Flat 2026 Financial Guidance 1. Represents a non-GAAP financial measure. Refer to “Non-G
Slide 15: Disciplined Capital Deployment
Disciplined Capital Deployment 1. Adjusted EBITDA is a non-GAAP financial measure. Refer to “Non-GAAP Financial Measures” on slide 2 2. Net debt/adjusted EBITDA is calculated based on financial data provided by Collegium in its press release on Form 8-K and Quarterly Report on Form 10-Q filed with t
Slide 16: Closing Remarks
Closing Remarks Vikram Karnani President & Chief Executive Officer
Slide 17: Serving Patients and Creating Value for Shareholders
Serving Patients and Creating Value for Shareholders 17 17 2026 STRATEGIC PRIORITIES 1. Drive further growth for the ADHD Portfolio 2. Maximize the durability of the Pain Portfolio 3. Strategically deploy capital • Business Development • Debt repayment • Share repurchases VALUE CREATION Grow Revenue
Slide 18: A commercial-stage biopharmaceutical company focused on improving the lives of people living with serious
A commercial-stage biopharmaceutical company focused on improving the lives of people living with serious neurological and pain conditions
Slide 19: Non-GAAP Reconciliations
Non-GAAP Reconciliations A <@® Collegium. PHARMACEUTICAL
Slide 20: Reconciliation of GAAP Net Income to Adjusted EBITDA
Reconciliation of GAAP Net Income to Adjusted EBITDA (in thousands, unaudited) 20 Three Months Ended September 30, Nine Months Ended September 30, 2026 2025 2026 2025 GAAP net (loss) income $ 21,759 $ 31,507 $ 21,204 $ 45,907 Adjustments: Interest expense 21,943 21,767 57,324 63,020 Interest income
Slide 21: Reconciliation of GAAP Operating Expenses to Adjusted Operating Expenses
Reconciliation of GAAP Operating Expenses to Adjusted Operating Expenses (in thousands, unaudited) 21 Three Months Ended September 30, Nine Months Ended September 30, 2026 2025 2026 2025 GAAP operating expenses $ 96,696 $ 67,084 $ 289,640 $ 216,000 Adjustments: Stock-based compensation 12,445 9,811
Slide 22: Reconciliation of GAAP Net Income to Adjusted Net Income and Adjusted EPS
Reconciliation of GAAP Net Income to Adjusted Net Income and Adjusted Earnings Per Share (in thousands, except share and per share amounts, unaudited) (1) The income tax effect of the adjustments was calculated by applying our blended federal and state statutory rate to the items that have a tax eff
Collegium Pharmaceutical — Q3 2026 Earnings Presentation on 6ix